RESEARCH ARTICLE

Prognostic significance of marital status in breast cancer survival: A population-based study

María Elena Martínez1,2*, Jonathan T. Unkart1,2, Li Tao4, Candyce H. Kroenke5, Richard Schwab1, Ian Komenaka6, Scarlett Lin Gomez4,7

1 Moores Cancer Center, University of California, San Diego, La Jolla, CA, United States of America, 2 Department of Family Medicine and Public Health, University of California, San Diego, La Jolla, CA, United States of America, 3 Department of Surgery, University of California, San Diego, La Jolla, CA, United States of America, 4 Cancer Prevention Institute of California, Fremont, CA, United States of America, 5 Kaiser Permanente, Division of Research, Oakland, CA, United States of America, 6 Maricopa Medical Center, Department of Surgery, Phoenix, AZ, United States of America, 7 Stanford Cancer Institute, Palo Alto, CA, United States of America

* e8martinez@ucsd.edu

Abstract

Research shows that married cancer patients have lower mortality than unmarried patients but few data exist for breast cancer. We assessed total mortality associated with marital status, with attention to differences by race/ethnicity, tumor subtype, and neighborhood socioeconomic status (nSES). We included, from the population-based California Cancer Registry, women ages 18 and older with invasive breast cancer diagnosed between 2005 and 2012 with follow-up through December 2013. We estimated mortality rate ratios (MRR) and 95% confidence intervals (CI) for total mortality by nSES, race/ethnicity, and tumor subtype. Among 145,564 breast cancer cases, 42.7% were unmarried at the time of diagnosis. In multivariable-adjusted models, the MRR (95% CI) for unmarried compared to married women was 1.28 (1.24–1.32) for total mortality. Significant interactions were observed by race/ethnicity (P < 0.001), tumor subtype (P < 0.001), and nSES (P = 0.009). Higher MRRs were observed for non-Hispanic whites and Asians/Pacific Islanders than for blacks or Hispanics, and for HR+/HER2+ tumors than other subtypes. Assessment of interactive effect between marital status and nSES showed that unmarried women living in low SES neighborhoods had a higher risk of dying compared with married women in high SES neighborhoods (MRR = 1.60; 95% CI: 1.53–1.67). Unmarried breast cancer patients have higher total mortality than married patients; the association varies by race/ethnicity, tumor subtype, and nSES. Unmarried status should be further evaluated as a breast cancer prognostic factor. Identification of underlying causes of the marital status associations is needed to design interventions that could improve survival for unmarried breast cancer patients.
Introduction
A growing body of evidence shows that mortality following a cancer diagnosis is higher in unmarried than married patients [1–4]. However, studies on the association specific to breast cancer are limited [5, 6], despite this being the most common cancer in women. Some published reports included marital status as a covariate in multivariable analyses [7–9], but, to our knowledge, a focused examination of the specific effect of marital status on breast cancer survival in different racial/ethnic populations or by tumor subtype has not been reported.

A population-based study published in 2005 [6] showed that compared to married breast cancer patients, unmarried women were more likely to be diagnosed with later stage disease and to die of breast cancer, and were less likely to receive definitive treatment, even after controlling for stage, treatment, socioeconomic factors, and comorbidities. A more recent study conducted in a safety net hospital reported an over 2-fold increase in breast cancer mortality in single versus married breast cancer patients [5]. However, none of these studies examined whether the marital status effects on survival differ across patient subgroups or tumor subtypes.

We recently reported significant heterogeneity in the association between marital status and survival across racial/ethnic and nativity groups [4]; however, this research was not specific to breast cancer. Understanding the extent to which marital status impacts survival after breast cancer diagnosis across sociodemographic groups is needed to help target interventions. However, there are limited data regarding the extent to which marriage benefits survival in these groups. Importantly, since breast cancer is recognized to be a heterogeneous disease, data are needed on how the marital status associations with mortality differ by tumor subtype. Using data from the population-based California Cancer Registry (CCR), we conducted a comprehensive examination of the association of marital status and total mortality among women diagnosed with invasive breast cancer. Specifically, we assessed main effects of being unmarried and total mortality and whether the association varied by race/ethnicity, neighborhood socioeconomic status (nSES), and tumor subtype.

Materials and methods
Study population
We obtained from the CCR information on 152,380 female California residents age 18 and above who were diagnosed with a first primary invasive breast cancer [International Classification of Disease for Oncology, 3rd Edition, (ICD-O-3) site codes C50.0–50.9, with the following ICD-O-3 coded histological subtypes of breast carcinoma or adenocarcinoma: 8000, 8001, 8010, 8020, 8022, 8050, 8140, 8201, 8211, 8230, 8255, 8260, 8401, 8453, 8480, 8481, 8500–8530, and 8575] during the period January 1, 2005 through December 31, 2012. We excluded patients who had no information on marital status at diagnosis (n = 6,179) and who were diagnosed by mammography/xerography (n = 70) or death certificate/autopsy (n = 567), and thereby included 145,564 patients in the final analysis.

CCR data on race, ethnicity, birthplace, and marital status were abstracted from medical records of reporting facilities and are based primarily on self-report. We also obtained from the CCR data on address at diagnosis (geocoded to census block group), American Joint Committee on Cancer (AJCC) stage, tumor size, lymph node involvement, grade, primary source of payment at the time of initial diagnosis and/or treatment, as well as treatment modalities (surgery, type of surgery, chemotherapy, and radiation therapy).

Birthplace is coded as US- or foreign-born. As previous research shows that birthplace is differentially missing in the cancer registry data between US- and foreign-born Hispanics and Asians/Pacific Islanders (APIs) [10, 11], we imputed nativity using patients’ social security
numbers (SSN) for the 33% of Hispanics and 30% of APIs with missing registry birthplace. This validated imputation method assigns a foreign birthplace to Hispanic patients who received their SSNs after the age of 24 and to APIs after the age of 20 [12, 13]. Patient residential address at diagnosis was geocoded and assigned to a census block group, then linked to nSES indices developed through principal components analyses. The two indices, based on Census 2000 data (for cases diagnosed in 2005) and American Community Survey 2007–2011 data (for cases diagnosed 2006–2012), were developed separately but included the same components: education, occupation, employment, household income, poverty, rent and house values. [14, 15]. Vital status as of December 31, 2013 was obtained through linkages to various vital records databases.

The CCR has collected information on the expression of ER and PR since 1990 and of HER2 since 1999 [16]. Data completeness for HER2 is over 80% since 2005. Each marker was coded as positive, negative, borderline, not tested/recorded, or unknown, based on the results of the test performed at the reporting facility. We classified breast cancers into four mutually exclusive subtypes: HR+/HER2- was defined as ER and/or PR positive and HER2 negative; HR+/HER2+ as ER and/or PR positive and HER2 positive; HR-/HER2+ as ER and PR negative and HER2 positive; and triple-negative breast cancer as ER, PR, and HER2 negative [16–20].

Statistical analysis

We used multivariable-adjusted Cox proportional hazards regression models to estimate hazard rate ratios (MRR) [21] and 95% confidence intervals (CI) [22] to evaluate differences in total mortality between married and unmarried (never married, separated, divorced, and widowed) breast cancer patients. The proportional hazards assumption was assessed for marital status and for each covariate by examining the correlation between weighted Schoenfeld residuals and logarithmically transformed survival time; no significant violations of the assumption were observed, except for stage. Thus, stage was included as a stratifying variable in all Cox regression models, allowing the baseline hazard to vary by stage. The models were adjusted for age, race/ethnicity, tumor subtype, treatment, lymph node involvement, tumor size, grade, histology, insurance status, and nSES. In our prior work, we found evidence of interaction between marital status and nSES; thus, statistical significance of multiplicative interaction effect of marital status and nSES was estimated with the Wald test by including a cross-product term in the Cox models. We also conducted separate analyses by race/ethnicity, tumor subtype, nSES, nativity among Hispanics and APIs, and for the six largest API ethnic groups: Chinese, Japanese, Filipino, Korean, South Asian, and Vietnamese. Cox regression and the Kaplan-Meier method was used to test statistical differences in overall survival by both marital status and nSES. All Cox regression models were adjusted for clustering by census block group. All statistical tests were carried out using SAS software version 9.3 (SAS Institute, Cary, North Carolina). All \( P \) values reported were two-sided, and those that were \( < 0.05 \) were considered to be statistically significant.

Results

Characteristics of study population

Among the 145,564 breast cancer patients included in the analyses, 22,610 deaths from any cause occurred during a total of 620,692 person-years of follow-up. At the time of diagnosis, the percent of married, single/separated/divorced, and widowed women was 57.3%, 28.5%, and 14.2%, respectively. Table 1 shows that widowed women were more likely to be older and to be non-Hispanic white (NHW), and less likely to be uninsured than married or single
Table 1. Sociodemographic, clinical, and treatment characteristics of patients diagnosed with breast cancer, according to marital status, California, 2005–2012.

|                | All N = 145564 | Married N = 83383 | Single/Separated/Divorced N = 41521 | Widowed N = 20660 |
|----------------|----------------|------------------|------------------------------------|------------------|
| **Sociodemographic Characteristics** |                |                  |                                    |                  |
| Age, years     |                |                  |                                    |                  |
| <35            | 3108 (2.1)     | 1665 (2.0)       | 1429 (3.4)                         | 14 (0.1)         |
| 35–49          | 32321 (22.2)   | 21433 (25.7)     | 10512 (25.3)                       | 376 (1.8)        |
| 50–59          | 37273 (25.6)   | 23943 (28.7)     | 11892 (28.6)                       | 1438 (7.0)       |
| 60–64          | 18697 (12.8)   | 11408 (13.7)     | 5742 (13.8)                        | 1547 (7.5)       |
| 65–69          | 16677 (11.5)   | 9531 (11.4)      | 4646 (11.2)                        | 2500 (12.1)      |
| 70–74          | 12682 (8.7)    | 6677 (8.0)       | 2981 (7.2)                         | 3024 (14.6)      |
| ≥75            | 24806 (17.0)   | 8726 (10.5)      | 4319 (10.4)                        | 11761 (56.9)     |
| Race/ethnicity |                |                  |                                    |                  |
| Non-Hispanic white | 90349 (62.1) | 51715 (62.0)     | 24401 (58.8)                       | 14233 (68.9)     |
| Black          | 9324 (6.4)     | 3309 (4.0)       | 4627 (11.1)                        | 1388 (6.7)       |
| Hispanic       | 26103 (17.9)   | 15140 (18.2)     | 8108 (19.5)                        | 2855 (13.8)      |
| Asian/Pacific Islander | 18374 (12.6) | 12478 (15.0) | 3896 (9.4) | 2000 (9.7) |
| Other/unknown  | 1414 (1.0)     | 741 (0.9)        | 489 (1.2)                          | 184 (0.9)        |
| Neighborhood (block group) statewide SES quintile |                |                  |                                    |                  |
| 1st (lowest)   | 18450 (12.7)   | 8686 (10.4)      | 6815 (16.4)                        | 2949 (14.3)      |
| 2nd            | 25289 (17.4)   | 13016 (15.6)     | 8106 (19.5)                        | 4167 (20.2)      |
| 3rd            | 29720 (20.4)   | 16423 (19.7)     | 8814 (21.2)                        | 4483 (21.7)      |
| 4th            | 34088 (23.4)   | 19988 (24.0)     | 9398 (22.6)                        | 4702 (22.8)      |
| 5th (highest)  | 38017 (26.1)   | 25270 (30.3)     | 8388 (20.2)                        | 4359 (21.1)      |
| Insurance status |                |                  |                                    |                  |
| No insurance   | 24509 (16.8)   | 14679 (17.6)     | 7476 (18.0)                        | 2354 (11.4)      |
| Private        | 67632 (46.5)   | 43916 (52.7)     | 18306 (44.1)                       | 5410 (26.2)      |
| Medicare or Medicare+Private | 18742 (12.9) | 9324 (11.2) | 3715 (8.9) | 5703 (27.6) |
| Any Public/Medicaid/Military | 30452 (20.9) | 13063 (15.7) | 10907 (26.3) | 6482 (31.4) |
| Unknown        | 4229 (2.9)     | 2401 (2.9)       | 1117 (2.7)                         | 711 (3.4)        |
| **Clinical Characteristics** |                |                  |                                    |                  |
| AJCC Stage     |                |                  |                                    |                  |
| I              | 66046 (45.4)   | 39638 (47.5)     | 17082 (41.1)                       | 9326 (45.1)      |
| II             | 48760 (33.5)   | 28144 (33.8)     | 14194 (34.2)                       | 6422 (31.1)      |
| III            | 17754 (12.2)   | 9756 (11.7)      | 5711 (13.8)                        | 2287 (11.1)      |
| IV             | 6982 (4.8)     | 3084 (3.7)       | 2729 (6.6)                         | 1169 (5.7)       |
| Unknown        | 6022 (4.1)     | 2761 (3.3)       | 1805 (4.3)                         | 1456 (7.0)       |
| Molecular subtype |            |                  |                                    |                  |
| HR+/HER2-      | 87989 (60.4)   | 50813 (60.9)     | 24510 (59.0)                       | 12666 (61.3)     |
| HR+/HER2+      | 14538 (10.0)   | 8573 (10.3)      | 4379 (10.5)                        | 1586 (7.7)       |
| HR-/HER2+      | 7274 (5.0)     | 4329 (5.2)       | 2116 (5.1)                         | 829 (4.0)        |
| Triple negative | 15106 (10.4) | 8705 (10.4) | 4604 (11.1) | 1797 (8.7) |
| Unclassified   | 20657 (14.2)   | 10963 (13.1)     | 5912 (14.2)                        | 3782 (18.3)      |
| Lymph node involvement |                |                  |                                    |                  |
| Negative       | 92823 (63.8)   | 53962 (64.7)     | 25195 (60.7)                       | 13666 (66.1)     |
| Positive       | 48757 (33.5)   | 27961 (33.5)     | 14966 (36.0)                       | 5830 (28.2)      |
| Unknown        | 3984 (2.7)     | 1460 (1.8)       | 1360 (3.3)                         | 1164 (5.6)       |

(Continued)
patients. Married women were less likely to reside in low SES neighborhoods and more likely to have private insurance than unmarried women. In regard to tumor subtype, widowed patients had a lower proportion of HER2+ and triple negative tumors than other women. Widowed women were less likely to undergo surgery and to have chemotherapy or radiation therapy than other women.

Marital status and mortality

After multivariable adjustment, total mortality was 28% higher in unmarried compared to married patients (Table 2). Among unmarried patients, the MRR was significantly higher in

### Table 1. (Continued)

|                  | All N = 145564 | Married N = 83383 | Single/Separated/Divorced N = 41521 | Widowed N = 20660 |
|------------------|---------------|-------------------|------------------------------------|-------------------|
| **Tumor Size (cm)** |               |                   |                                    |                   |
| 0.10 < tumor ≤ 0.50 | 9459 (6.5)    | 5863 (7.0)        | 2444 (5.9)                         | 1152 (5.6)        |
| 0.50 < tumor ≤ 1.00 | 22449 (15.4)  | 13550 (16.3)      | 5620 (13.5)                        | 3279 (15.9)       |
| 1.00 < tumor ≤ 2.00 | 48621 (33.4)  | 28997 (34.8)      | 13043 (31.4)                       | 6581 (31.9)       |
| 2.00 < tumor ≤ 5.00 | 45579 (31.3)  | 25372 (30.4)      | 13711 (33.0)                       | 6496 (31.4)       |
| >5.00             | 11006 (7.6)   | 5474 (6.6)        | 3984 (9.6)                         | 1548 (7.5)        |
| **Microinvasion** |               |                   |                                    |                   |
| Microinvasive     | 1546 (1.1)    | 962 (1.2)         | 414 (1.0)                          | 170 (0.8)         |
| Diffused          | 757 (0.5)     | 364 (0.4)         | 300 (0.7)                          | 93 (0.5)          |
| Unknown           | 6147 (4.2)    | 2801 (3.4)        | 2005 (4.8)                         | 1341 (6.5)        |
| **Grade**         |               |                   |                                    |                   |
| Grade I           | 30988 (21.3)  | 18109 (21.7)      | 8218 (19.8)                        | 4661 (22.6)       |
| Grade II          | 58240 (40.0)  | 33593 (40.3)      | 16211 (39.0)                       | 8436 (40.8)       |
| Grade III/IV      | 46587 (32.0)  | 26937 (32.3)      | 14123 (34.0)                       | 5527 (26.8)       |
| Unknown           | 9749 (6.7)    | 4744 (5.7)        | 2969 (7.2)                         | 2036 (9.9)        |
| **Histology**     |               |                   |                                    |                   |
| Ductal            | 111557 (76.6) | 64600 (77.5)      | 32104 (77.3)                       | 14853 (71.9)      |
| Lobular           | 23418 (16.1)  | 13620 (16.3)      | 6262 (15.1)                        | 3536 (17.1)       |
| Other             | 10589 (7.3)   | 5163 (6.2)        | 3155 (7.6)                         | 2271 (11.0)       |
| **Treatment**     |               |                   |                                    |                   |
| Surgery           |               |                   |                                    |                   |
| No surgery        | 10368 (7.1)   | 4161 (5.0)        | 3783 (9.1)                         | 2424 (11.7)       |
| Breast conserving surgery | 78579 (54.0) | 46247 (55.5) | 21609 (52.0) | 10723 (51.9) |
| Mastectomy        | 56339 (38.7)  | 32845 (39.4)      | 16053 (38.7)                       | 7441 (36.0)       |
| Other/unknown     | 278 (0.2)     | 130 (0.2)         | 76 (0.2)                           | 72 (0.3)          |
| Chemotherapy      |               |                   |                                    |                   |
| No                | 83953 (57.7)  | 45097 (54.1)      | 22580 (54.4)                       | 16276 (78.8)      |
| Yes               | 59274 (40.7)  | 36972 (44.3)      | 18265 (44.0)                       | 4037 (19.5)       |
| Unknown           | 2337 (1.6)    | 1314 (1.6)        | 676 (1.6)                          | 347 (1.7)         |
| Radiation therapy |               |                   |                                    |                   |
| No                | 76327 (52.4)  | 41365 (49.6)      | 22165 (53.4)                       | 12797 (61.9)      |
| Yes               | 69109 (47.5)  | 41978 (50.3)      | 19330 (46.6)                       | 7801 (37.8)       |
| Unknown           | 128 (0.1)     | 40 (0.0)          | 26 (0.1)                           | 62 (0.3)          |

Abbreviations: SES = socioeconomic status; AJCC = American Joint Committee on Cancer; HR = hormone receptor; HER2 = human epidermal receptor 2

https://doi.org/10.1371/journal.pone.0175515.t001
widowed (MRR = 1.35; 95% CI, 1.30–1.41) than single/separated/divorced women (MRR = 1.24; 95% CI, 1.20–1.28), based on non-overlapping CIs.

We next assessed whether there was variation in the MRRs for marital status and mortality by race/ethnicity, nativity (among Hispanics and APIs), nSES, or tumor subtype (Table 3). Significant variation by race/ethnicity was shown (P-heterogeneity < 0.0001), albeit the magnitude of the differences was modest. Among API ethnic groups, we noted significant associations for total mortality for Filipinos and other Asians, but numbers of events were limited in other ethnic groups. Assessing differences by nativity, no significant differences were shown among APIs, whereas significant variation was observed for Hispanics. The marital status-mortality associations were higher in US-born than foreign-born Hispanics (P-heterogeneity = 0.01) and significant variation by nSES was shown (P-heterogeneity = 0.009). Differences across tumor subtype for the marital status and mortality association were also evident, with higher MRRs observed for HR+/HER2- tumors (MRR = 1.32; 95% CI: 1.26–1.37) and lower for triple negative tumors (MRR = 1.16; 95% CI: 1.08–1.25). In all analyses performed, results for breast cancer-specific mortality were similar to those observed for all-cause mortality (data not shown). Also, since the proportion of individuals living with an unmarried partner in the U.S. has increased over time [23] and we are lacking these data in the registry, we restricted analyses to women <64 years of age, in whom cohabitation might be higher than in older patients. Results show no material differences in the MRRs as compared to the total population (data not shown).

Lastly, we assessed mortality and the interactive effects of marital status and nSES. As shown in Fig 1, survival was highest among married women who resided in high SES neighborhoods and lowest among unmarried women in low SES neighborhoods. When we conducted multivariable analyses, a similar pattern emerged (Fig 2 and S1 Table). Compared to married women who resided in high SES neighborhoods, patients with all other combinations of marital status (married/unmarried) and SES (low/high) had higher risk of total mortality. In all women, the strongest association was shown for unmarried patients living in low SES neighborhoods (MRR = 1.60; 95% CI, 1.53–1.67), which was also evident when we stratified by tumor subtype. The largest mortality difference by SES/marital status group was seen for women with HR+/HER2- and the smallest was observed for patients with triple negative tumors (Fig 2).

Table 2. Adjusted mortality rate ratio (MRR) and 95% confidence intervals (CI) for total cancer mortality associated with marital status, California, 2005–2012.

| Marital status at diagnosis | Total mortality |
|-----------------------------|----------------|
|                             | No. of deaths | MRR\(^\text{a}\) (95%CI) |
| Married                     | 9304          | 1.00 (Reference) |
| All unmarried               | 13306         | 1.28 (1.24–1.32) |
| Single/Separated/Divorced   | 6941          | 1.24 (1.20–1.28) |
| Widowed                     | 6365          | 1.35 (1.30–1.41) |

\(^{a}\)Estimated from Cox proportional hazard models, stratified by stage (AJCC stage I-IV or unknown) and adjusted for: age (continuous); race/ethnicity (NHW, non-Hispanic white, black, Hispanic, Asian/Pacific Islander, other/unknown); tumor subtype HR+/HER2-, HR+/HER2+, HR-/HER2, triple negative, and unclassified; first course of treatment (Y/N for surgery, radiation, hormone therapy); lymph node involvement (negative, positive, unknown); tumor size (continuous); grade (I, II, III/IV, unknown); histology (ductal, lobular, other); insurance status (no insurance, private insurance only, Medicare only/Medicare + private insurance, any public/Medicaid/military insurance, unknown); and neighborhood socioeconomic status (quintiles).

https://doi.org/10.1371/journal.pone.0175515.t002
Table 3. Adjusted mortality rate ratios (MRR) and 95% confidence intervals (CIs) for total mortality associated with unmarried vs. married patients, by race/ethnicity, tumor subtype, neighborhood socioeconomic status (SES), nativity, and Asian/Pacific Islander (API) subgroups, California, 2005–2012.

| Total mortality | No. of deaths Unmarried | No. of deaths Married | MRR\(^a\) (95\%CI) Unmarried vs. Married |
|-----------------|-------------------------|-----------------------|-----------------------------------------|
| **By Race/ethnicity** |                         |                       |                                         |
| Non-Hispanic white | 8761                    | 5858                  | 1.31 (1.26–1.36)                        |
| Black            | 1599                    | 614                   | 1.17 (1.05–1.30)                        |
| Hispanic          | 1943                    | 1750                  | 1.15 (1.07–1.24)                        |
| Asian/Pacific Islander | 894                    | 1006                  | 1.29 (1.16–1.43)                        |
| Other/unknown    | 109                     | 76                    | 1.06 (0.74–1.53)                        |
| **P-heterogeneity\(^b\)** |                         |                       | <0.001                                  |
| **Among APIs by ethnic group** |                    |                       |                                         |
| Chinese          | 167                     | 227                   | 1.21 (0.95–1.54)                        |
| Japanese         | 125                     | 92                    | 1.33 (0.96–1.83)                        |
| Filipino         | 305                     | 321                   | 1.24 (1.03–1.50)                        |
| Other Asian      | 138                     | 135                   | 1.35 (1.02–1.79)                        |
| Korean           | 52                      | 68                    | 1.38 (0.89–2.15)                        |
| South Asian      | 47                      | 84                    | 0.84 (0.53–1.33)                        |
| Vietnamese       | 60                      | 79                    | 1.03 (0.68–1.56)                        |
| **P-heterogeneity\(^b\)** |                         |                       | 0.6183                                  |
| **Among Hispanics by nativity** |                  |                       |                                         |
| US-born          | 948                     | 727                   | 1.23 (1.10–1.37)                        |
| Foreign-born     | 995                     | 1023                  | 1.07 (0.97–1.18)                        |
| **P-heterogeneity\(^b\)** |                         |                       | 0.010                                   |
| **Among APIs by nativity** |                  |                       |                                         |
| US-born          | 168                     | 128                   | 1.62 (1.25–2.11)                        |
| Foreign-born     | 722                     | 876                   | 1.25 (1.12–1.41)                        |
| **P-heterogeneity\(^b\)** |                         |                       | 0.425                                   |
| **By Neighborhood SES** |                  |                       |                                         |
| 1st (lowest)     | 2526                    | 1357                  | 1.22 (1.13–1.32)                        |
| 2nd              | 2918                    | 1804                  | 1.26 (1.18–1.35)                        |
| 3rd              | 2857                    | 2009                  | 1.33 (1.24–1.42)                        |
| 4th              | 2751                    | 2068                  | 1.22 (1.14–1.30)                        |
| 5th (highest)    | 2254                    | 2066                  | 1.32 (1.24–1.42)                        |
| **P-heterogeneity\(^b\)** |                         |                       | 0.009                                   |
| **By Tumor Subtype** |                  |                       |                                         |
| HR+/HER2-        | 5939                    | 4102                  | 1.32 (1.26–1.37)                        |
| HR+/HER2+        | 1157                    | 899                   | 1.18 (1.07–1.30)                        |
| HR-/HER2+        | 779                     | 705                   | 1.21 (1.07–1.35)                        |
| Triple negative  | 1961                    | 1803                  | 1.16 (1.08–1.25)                        |
| Unclassified     | 3470                    | 1795                  | 1.35 (1.25–1.46)                        |
| **P-heterogeneity\(^b\)** |                         |                       | <0.0001                                 |

\(^a\) Estimated from Cox proportional hazard models, stratified by stage (AJCC stage I-IV or unknown) and adjusted for: age continuous); race/ethnicity (NHW, non-Hispanic white, black, Hispanic, Asian/Pacific Islander, other/unknown); tumor subtype HR+/HER2-, HR+/HER2+, HR-/HER2, triple negative, and unclassified); first course of treatment (Y/N for surgery, radiation, hormone therapy); lymph node involvement (negative, positive, unknown); tumor size (continuous); grade (I, II, II/IV, unknown); histology (ductal, lobular, other); insurance status (no insurance, private insurance only, Medicare only/Medicare + private insurance, any public/Medicaid/military insurance, unknown); and neighborhood socioeconomic status (quintiles).

\(^b\) Likelihood ratio test for interaction computed based on cross-product terms.

https://doi.org/10.1371/journal.pone.0175515.t003
Discussion

Results of our population-based study show that breast cancer patients who were unmarried at diagnosis had a significantly higher risk of dying of all causes compared with those who were married. Additionally, larger associations among NHW and API women, US-born Hispanics and APIs, and patients diagnosed with HR+/HER2- tumors were observed.

Although there is a growing body of evidence on the adverse effects of being unmarried compared to being married on cancer mortality [1, 3, 4, 24–26], data specific to breast cancer

Fig 1. Kaplan-Meier curve of all-cause survival by marital status and neighborhood SES, California, 2005–2012.

https://doi.org/10.1371/journal.pone.0175515.g001

Fig 2. Hazard ratios for total mortality and marital status plus neighborhood socioeconomic status (SES), California, 2005–2012. Hazard ratios estimated from Cox proportional hazard models adjusted for: age at diagnosis (continuous), race/ethnicity, subtype (for analysis of all patients), lymph node involvement, tumor size, grade, histological subtypes, first course of treatment, insurance status; AJCC stage I-IV or unknown is included as a stratifying variable. High SES group includes neighborhood SES quintiles 4–5 and low SES group includes quintiles 1–3. Numbers represent hazard ratio and bars represent 95% confidence interval for each group. *Denotes statistical significance, whereby the confidence intervals do not include 1. Abbreviations: MRR = hormone receptor; HER2 = human epidermal receptor 2; Ref = reference group.

https://doi.org/10.1371/journal.pone.0175515.g002
as well as the effect of marital status on mortality by race/ethnicity are sparse, as prior studies have lacked sufficient sample size to evaluate these associations. Our prior research showed higher mortality rates among foreign-born relative to US-born APIs with breast cancer, but lower mortality among foreign-born relative to US-born Hispanics [27, 28]. The smaller effects for marital status on mortality among foreign-born API patients and lack of marriage effect among foreign-born Hispanics in the current study may contribute to the understanding of factors underlying the survival differences between immigrants and their US-born counterparts, which merits further study. Specifically, API immigrant breast cancer patients may face more extreme burdens, such as language barriers, cultural beliefs, and immigration-associated stress, that limit their ability to benefit from quality access to care and receipt of guideline treatments; these ethnic- and culturally-specific factors may diminish the potentially beneficial effects of marriage. On the other hand, immigrant Hispanic breast cancer patients may have already strong social ties and support from their co-ethnic social networks, that any additional benefits of marriage may be minimal [29].

We know of no published reports where the association of marital status and mortality in breast cancer patients has been assessed according to tumor subtype. Given that breast cancer is considered a heterogeneous disease, this is an important consideration. Indeed, results of our study showed significant heterogeneity by tumor subtype, with highest association observed in HR+/HER2- and lowest in triple negative tumors. Triple negative breast cancer is known to be an aggressive subtype with poor prognosis and few treatment options [16]. The beneficial effects of marriage seen in other tumor subtypes with longer life expectancy may not be as relevant in aggressive and rapidly-progressing tumors characterized by few treatment options. This is consistent with our prior report [3], where MRRs for total mortality and marital status were stronger in cancers with better prognosis, including prostate and non-Hodgkin lymphoma.

Published data on the positive associations between being married and undergoing mammography screening [30] and with breast cancer treatment uptake [31, 32] may explain some of the associations between marital status and mortality following breast cancer diagnosis, although the beneficial effect of marriage on breast cancer survival persists after accounting for treatment [6]. Two main pathways have been proposed to explain the benefits of marital status on cancer and overall longevity [33]: better economic resources and greater social support. In regard to the first pathway, we previously assessed the effect of nSES and health insurance status on overall survival from the 10 most common cancers [3]. Our results suggested that the higher mortality associated with being unmarried vs. married was not explained by the availability of financial resources [34]. MRRs unadjusted for nSES and health insurance were 1.27 for males and 1.19 for females and attenuated slightly to 1.22 and 1.15, respectively, after adjustment for these two economic-related variables. In fact, the significant interaction seen in the analysis of the cross-classification of marital status and nSES in this report suggests that the lack of neighborhood resources may compound, rather than explain, the effect of unmarried status on outcomes. Marital ties increase social network size not just through availability of a partner but through access to the partner’s network ties, while nSES may reflect social capital as well as proxy of individual-level SES. Significant additive and interactive effects seen in these analyses suggest that both high SES neighborhoods and marital ties each confer different and critical resources predictive of survival.

Relative to the social support pathway, prior research shows better breast cancer survival among patients with a larger number of social ties [2, 35–37] and with greater social support [38, 39]. However, data on these specific contextual factors and whether they mediate or moderate the marital status association are not known. Women’s social relationships have been shown to influence choice of mastectomy or lumpectomy [40], whether to pursue chemotherapy [41],
and other treatment decisions [41]. A marital partner may also provide critical support that helps improve health behaviors. In a recent study, women with breast cancer who were unmarried were more likely to be current smokers and less likely to receive chemotherapy [42]. Cluze et al. [43] also reported that a larger number of family members or friends supporting the breast cancer patient was associated with better adherence to adjuvant endocrine therapy. Clinical implications of these and our current results are evident, including awareness among oncologists and other cancer providers to recognize unmarried patients as a high-risk group for higher mortality. Consequently, it may be beneficial to involve nurse case managers, clinical social workers and/or psychologists at various points during a patient’s prolonged treatment course. For the research community, it is important to note that data on social factors and social support as an explanatory factor for the reported association between marital status and mortality in cancer patients are limited, requiring much needed work focused on exploring possible mechanisms to guide future interventions. Biologic mechanisms potentially responsible for poor social support and isolation associated with breast cancer progression include immune, endocrine function, and stress-related factors [44], variables that have been linked with tumor growth and progression in breast cancer animal models and human studies [45–47].

Results of our study must be interpreted in light of the limitations. Although it could be argued that assessing marital status at time of diagnosis is appropriate in terms of timing, we could not assess changes in marital status following a breast cancer diagnosis. It is also important to note that we lacked information on co-habitation, support from children and other family members, and quality of marriage. Cancer registry-recorded race, ethnicity, and birthplace may be subject to some misclassification; however, because this information is usually based on self-report (extracted from patient medical records) [48], it is generally accurate for most racial/ethnic groups [10, 11, 49–51]. However, because registry birthplace data are incomplete in a biased manner, we used a validated approach to impute nativity. Further, we lacked information on comorbidities, specific treatment modalities, which could be potential mediators or confounders in our analyses. Specifically, we do not have data on psychological and cultural factors, or levels of social support. As a result, we are not able to address specific contextual factors responsible for the observed associations between marital status and mortality. Our results may not be generalizable beyond the California population. We cannot dismiss the possibility of self-selection, whereby women who are physically, emotionally, or psychologically healthier may be more likely to marry than those who are not. In addition, selection out of marriage due to divorce might also contribute to this self-selection.

Our results show that breast cancer patients who are unmarried have higher all-cause mortality compared to married patients, but that this survival benefit varies across racial/ethnic groups, by tumor subtype, and nSES. These findings along with the growing body of evidence on this topic underscore the importance of identifying and examining the reasons for the gap in mortality in married versus unmarried patients. These data are urgently needed so that we can identify and implement targeted interventions that could help ameliorate the poorer survival among unmarried breast cancer patients.

Supporting information

S1 Table. Adjusted hazard ratios (MRR) and 95% confidence intervals (CIs) for total mortality associated with marital status plus neighborhood socioeconomic status (SES), California, 2005–2012. Abbreviations: HR = hormone receptor; HER2 = human epidermal receptor 2; Q = quintile.

*Estimated from Cox proportional hazard models adjusted for: age at diagnosis (continuous), race/ethnicity, subtype (for analysis of all patients), lymph node involvement, tumor size,
grade, histological subtypes, first course of treatment, insurance status; AJCC stage I-IV or unknown is included as a stratifying variable.

(DOCX)

Acknowledgments

We would like to thank Valesca Largaespada for her contribution in the manuscript preparation.

The collection of cancer incidence data used in this study was supported by the California Department of Public Health as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885; the National Cancer Institute’s Surveillance, Epidemiology and End Results Program under contract HHSN261201000140C awarded to the Cancer Prevention Institute of California, contract HHSN261201000035C awarded to the University of Southern California, and contract HHSN261201000034C awarded to the Public Health Institute; and the Centers for Disease Control and Prevention’s National Program of Cancer Registries, under agreement U58DP003862-01 awarded to the California Department of Public Health. The ideas and opinions expressed herein are those of the author(s) and endorsement by the State of California, Department of Public Health the National Cancer Institute and the Centers for Disease Control and Prevention or their Contractors and Sub-contractors is not intended nor should be inferred.

Author Contributions

Conceptualization: MEM SG.
Data curation: LT.
Formal analysis: LT.
Funding acquisition: SG MEM.
Investigation: MEM SG.
Methodology: MEM SG LT.
Project administration: MEM.
Resources: MEM LT.
Software: SG.
Supervision: MEM.
Validation: MEM SG.
Visualization: MEM SG LT.
Writing – original draft: MEM SG JTU.
Writing – review & editing: JTU RS CHK IK.

References

1. Aizer AA, Chen MH, McCarthy EP, Mendu ML, Koo S, Wilhite TJ, et al. Marital status and survival in patients with cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2013; 31(31):3869–76.
1. Martinez ME, Anderson K, Murphy JD, Hurley S, Canchola AJ, Keegan TH, et al. Differences in marital status and mortality by race/ethnicity and nativity among California cancer patients. Cancer. 2016; 122(10):1570–8. https://doi.org/10.1002/cncr.29886 PMID: 27065455
2. Pinquart M, Duberstein PR. Associations of social networks with cancer mortality: a meta-analysis. Critical reviews in oncology/hematology. 2010; 75(2):122–37. https://doi.org/10.1016/j.critrevonc.2009.06.003 PMID: 19604706
3. Gomez SL, Hurley S, Canchola AJ, Keegan THM, Cheng I, Murphy JD, et al. Effects of marital status and economic resources on survival after cancer: A population-based study. Cancer. 2016; 122(10):1618–25. https://doi.org/10.1002/cncr.29885 PMID: 27065317
4. Martinez ME, Anderson K, Murphy JD, Hurley S, Canchola AJ, Keegan TH, et al. Differences in marital status and mortality by race/ethnicity and nativity among California cancer patients. Cancer. 2016; 122(10):1570–8. https://doi.org/10.1002/cncr.29886 PMID: 27065455
5. Parikh DA, Chudasama R, Agarwal A, Rand A, Qureshi MM, Ngo T, et al. Race/Ethnicity, Primary Language, and Income Are Not Demographic Drivers of Mortality in Breast Cancer Patients at a Diverse Safety Net Academic Medical Center. International journal of breast cancer. 2015; 2015:835074. https://doi.org/10.1155/2015/835074 PMID: 26605089
6. Osborne C, Ostir GV, Du X, Peek MK, Goodwin JS. The influence of marital status on the stage at diagnosis, treatment, and survival of older women with breast cancer. Breast cancer research and treatment. 2005; 93(1):41–7. https://doi.org/10.1007/s10549-005-3702-4 PMID: 16184457
7. Chen DN, Song CG, Ouyang QW, Jiang YZ, Ye FG, Ma FJ, et al. Differences in breast cancer characteristics and outcomes between Caucasian and Chinese women in the US. Oncotarget. 2015; 6(14):12774–82. https://doi.org/10.18632/oncotarget.3666 PMID: 25904050
8. Thomas A, Khan SA, Chrischilles EA, Schroeder MC. Initial Surgery and Survival in Stage IV Breast Cancer in the United States, 1988–2011. JAMA surgery. 2015:1–8.
9. Bhuyan SS, Stimpson JP, Rajaram SS, Lin G. Mortality outcome among medically underserved women screened through a publicly funded breast cancer control program, 1997–2007. Breast cancer research and treatment. 2014; 146(1):221–7. https://doi.org/10.1007/s10549-014-2992-9 PMID: 24903224
10. Gomez SL, Glaser SL, Kelsey JL, Lee MM. Bias in completeness of birthplace data for Asian groups in a population-based cancer registry (United States). Cancer Causes Control. 2004; 15(3):243–53. https://doi.org/10.1023/B:CACO.0000024244.91775.64 PMID: 15090719
11. Gomez SL, Glaser SL. Quality of cancer registry birthplace data for Hispanics living in the United States. Cancer causes & control: CCC. 2005; 16(6):713–23.
12. Gomez SL, Quach T, Horn-Ross PL, Pham JT, Cockburn M, Chang ET, et al. Hidden breast cancer disparities in Asian women: disaggregating incidence rates by ethnicity and migrant status. American journal of public health. 2010; 100 Suppl 1:S125–31.
13. Keegan TH, John EM, Fish KM, Alfaro-Velcamp T, Clarke CA, Gomez SL. Breast cancer incidence patterns among California Hispanic women: differences by nativity and residence in an enclave. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2010; 19(5):1208–18.
14. Yang J, Schupp CW, Harrati A, Clarke C, Keegan TH, Gomez SL. Developing an area-based socioeconomic measure from American Community Survey data. 2014 Contract No.: May 7, 2014.
15. Yost K, Perkins C, Cohen R, Morris C, Wright W. Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer causes & control: CCC. 2001; 12(8):703–11.
16. Bauer KR, Brown M, Cress RD, Parise CA, Coggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 2007; 109(9):1721–8. https://doi.org/10.1002/cncr.22618 PMID: 17387718
17. Bernstein L, Lacey JV Jr. Receptors, associations, and risk factor differences by breast cancer subtypes: positive or negative? Journal of the National Cancer Institute. 2011; 103(6):451–3. https://doi.org/10.1093/jnci/djr046 PMID: 21346225
18. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/Collage of American Pathologists guideline recommendations for human epidural growth factor receptor 2 testing in breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2007; 25(1):118–45.
19. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006; 295(21):2492–502. https://doi.org/10.1001/jama.295.21.2492 PMID: 16757721
20. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747–52. https://doi.org/10.1038/35021093 PMID: 10963602
21. Waite LJ, Lehrer EL. The Benefits from Marriage and Religion in the United States: A Comparative Analysis. Population and development review. 2003; 29(2):255–76. PMID: 19129930
22. Manzoli L, Villari P, G MP, Boccia A. Marital status and mortality in the elderly: a systematic review and meta-analysis. Social science & medicine. 2007; 64(1):77–94.

23. Families and Living Arrangements. Living Arrangements of Adults: U.S. Census Bureau; 2016 [cited 2017 March 3]. Available from: https://www.census.gov/hhes/families/data/adults.html.

24. Goodwin JS, Hunt WC, Key CR, Samet JM. The effect of marital status on stage, treatment, and survival of cancer patients. Jama. 1987; 258(21):3125–30. PMID: 3669259

25. Kravdal O. The impact of marital status on cancer survival. Social science & medicine. 2001; 52 (3):357–68.

26. Lai H, Lai S, Krongrad A, Trapido E, Page JB, McCoy CB. The effect of marital status on survival in late-stage cancer patients: an analysis based on surveillance, epidemiology, and end results (SEER) data, in the United States. Int J Behav Med. 1999; 6(2):150–76. https://doi.org/10.1207/s15327558ijbm0602_4 PMID: 16250685

27. Gomez SL, Clarke CA, Shema SJ, Chang ET, Keegan TH, Glaser SL. Disparities in breast cancer survival among Asian women by ethnicity and immigrant status: a population-based study. Am J Public Health. 2010; 100(5):861–9. https://doi.org/10.2105/AJPH.2009.176651 PMID: 20299648

28. Keegan TH, Quach T, Shema S, Glaser SL, Gomez SL. The influence of nativity and neighborhoods on breast cancer stage at diagnosis and survival among California Hispanic women. BMC cancer. 2010; 10:603. https://doi.org/10.1186/1471-2407-10-603 PMID: 21050464

29. Ro A, Bostean G. Duration of U.S. stay and body mass index among Latino and Asian immigrants: A test of theoretical pathways. Social science & medicine. 2015; 144:39–47.

30. Patel K, Kanu M, Liu J, Bond B, Brown E, Williams E, et al. Factors influencing breast cancer screening in low-income African Americans in Tennessee. Journal of community health. 2014; 39(5):943–50. https://doi.org/10.1007/s10900-014-9834-x PMID: 24554393

31. Ayalew Ali A, Xiao H, Kirov GE. Health insurance and breast-conserving surgery with radiation treatment. The American journal of managed care. 2014; 20(6):502–16. PMID: 25180437

32. Elmore L, Deshpande A, Daly M, Margenthaler JA. Postmastectomy radiation therapy in T3 node-negative breast cancer. The Journal of surgical research. 2015; 199(1):90–6. https://doi.org/10.1016/j.jss.2015.04.012 PMID: 25976852

33. Rendall MS, Weden MM, Favreault MM, Waldron H. The protective effect of marriage for survival: a review and update. Demography. 2011; 49(2):481–506. https://doi.org/10.1007/s13524-011-0032-5 PMID: 21526396

34. Gomez SL, Hurley S, Canchola AJ, Keegan TH, Cheng I, Murphy JD, et al. Effects of marital status and economic resources on survival after cancer: A population-based study. Cancer. 2016; 122(10):1618–25. https://doi.org/10.1002/cncr.29885 PMID: 27065317

35. Kroenke CH, Kubzansky LD, Schemhammer ES, Holmes MD, Kawachi I. Social networks, social support, and survival after breast cancer diagnosis. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2006; 24(7):1105–11.

36. Kroenke CH, Kwan ML, Neugut AI, Ergas IJ, Wright JD, Caan BJ, et al. Social networks, social support mechanisms, and quality of life after breast cancer diagnosis. Breast cancer research and treatment. 2013; 139(2):515–27. https://doi.org/10.1007/s10549-013-2477-2 PMID: 23657404

37. Kroenke CH, Quesenberry C, Kwan ML, Sweeney C, Castillo A, Caan BJ. Social networks, social support, and burden in relationships, and mortality after breast cancer diagnosis in the Life After Breast Cancer Epidemiology (LACE) study. Breast cancer research and treatment. 2013; 137(1):261–71. https://doi.org/10.1007/s10549-012-2253-8 PMID: 23143212

38. Chou AF, Stewart SL, Wild RC, Bloom JR. Social support and survival in young women with breast carcinoma. Psychooncology. 2012; 21(2):125–33. https://doi.org/10.1002/pin.1863 PMID: 20967848

39. Eppler M, Zheng Y, Zheng W, Chen Z, Gu K, Penson D, et al. Quality of life after breast cancer diagnosis and survival. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2011; 29(4):406–12.

40. Hawley ST, Griggs JJ, Hamilton AS, Graff JJ, Janz NK, Morrow M, et al. Decision involvement and receipt of mastectomy among racially and ethnically diverse breast cancer patients. Journal of the National Cancer Institute. 2009; 101(19):1337–47. https://doi.org/10.1093/jnci/djp271 PMID: 19720966

41. Shelton RC, Clarke Hillyer G, Hershman DL, Lecoce N, Bovbjerg DH, Mandelblatt JS, et al. Interpersonal influences and attitudes about adjuvant therapy treatment decisions among non-metastatic breast cancer patients: an examination of differences by age and race/ethnicity in the BQUAL study. Breast cancer research and treatment. 2013; 137(3):817–28. https://doi.org/10.1007/s10549-012-2370-4 PMID: 23263696

42. Kroenke CH, Michael YL, Shu XO, Poole EM, Kwan ML, Nechuta S, et al. Post-diagnosis social networks, and lifestyle and treatment factors in the After Breast Cancer Pooling Project. Psychooncology. 2016.
43. Cluze C, Rey D, Huiart L, BenDiane MK, Bouhnik AD, Berenger C, et al. Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2012; 23(4):882–90.

44. Hinzey A, Gaudier-Diaz MM, Lustberg MB, DeVries AC. Breast cancer and social environment: getting by with a little help from our friends. Breast cancer research: BCR. 2016; 18(1):54. https://doi.org/10.1186/s13058-016-0700-x PMID: 27225892

45. Lutgendorf SK, Sood AK. Biobehavioral factors and cancer progression: physiological pathways and mechanisms. Psychosomatic medicine. 2011; 73(9):724–30. https://doi.org/10.1097/PSY.0b013e318235be76 PMID: 22021459

46. Sephton SE, Lush E, Dedert EA, Floyd AR, Rebholz WN, Dhabhar FS, et al. Diurnal cortisol rhythm as a predictor of lung cancer survival. Brain, behavior, and immunity. 2013; 30 Suppl:S163–70. https://doi.org/10.1016/j.bbi.2012.07.019 PMID: 22884416

47. Sephton SE, Sapolsky RM, Kraemer HC, Spiegel D. Diurnal cortisol rhythm as a predictor of breast cancer survival. Journal of the National Cancer Institute. 2000; 92(12):994–1000. PMID: 10861311

48. Gomez SL, Le GM, West DW, Satariano WA, O’Connor L. Hospital policy and practice regarding the collection of data on race, ethnicity, and birthplace. Am J Public Health. 2003; 93(10):1685–8. PMID: 14534222

49. Clegg LX, Reichman ME, Hankey BF, Miller BA, Lin YD, Johnson NJ, et al. Quality of race, Hispanic ethnicity, and immigrant status in population-based cancer registry data: implications for health disparity studies. Cancer causes & control: CCC. 2007; 18(2):177–87.

50. Gomez SL, Glaser SL. Quality of birthplace information obtained from death certificates for Hispanics, Asians, and Pacific Islanders. Ethnicity & disease. 2004; 14(2):292–5.

51. Gomez SL, Glaser SL. Misclassification of race/ethnicity in a population-based cancer registry (United States). Cancer causes & control: CCC. 2006; 17(6):771–81.